Enzymotec Presents Clinical Trials Strategy for Its Infant Nutrition Lipid Based Ingredients

KFAR BARUCH, Israel, September 11, 2012 /PRNewswire/ –

Enzymotec [http://www.enzymotec.com ] Ltd. reports today that clinical trials for its
lipid-based ingredient line for infant nutrition [http://www.enzymotec.com ] yielded
positive results. This plan is part of a comprehensive business development strategy to
develop and market directly or through its affiliated companies a line of products
mimicking the vital lipids found in mother’s milk, such as triglyceride, phospholipids and
long-chain polyunsaturated fatty acids (LCPUFA).

Enzymotec intends to publish four new scientific articles on its lipid-based
ingredients for infant nutrition in peer-reviewed journals in the coming months. These
large-scale clinical research trials were conducted on newborn term infants in several
institutes worldwide. Clinical results already have been presented at leading professional
conferences.

One of the studies recently completed was a controlled clinical trial on InFat(R).
InFat is a beta-palmitate ingredient that successfully mimics the fat composition and
properties of human milk fat. It enables easy digestion and optimized uptake of calcium,
fat recovery and energy. InFat is marketed by Advanced Lipids, a joint venture of AAK and
Enzymotec. The study was the first testing the positive effect of a commercial term-infant
formula containing beta-palmitate on Chinese infants’ well-being. It was conducted by
Professor Chen Yu-Ming, the principle investigator at Sun Yat-Sen University and in
collaboration with Enzymotec.

“The clinical trials plan represents Enzymotec’s ongoing commitment to explore the
special characteristics of human milk and demonstrate its lipid-based ingredients’ health
benefits on various infant populations,” says Yael Lifshitz, PhD, Director of R&D, of
Enzymotec Infant Nutrition. “We developed this innovative ingredient and educated the
premium infant formula market over the last several years. Enzymotec invested 10% of its
revenue in research and development-a percentage considered among the highest in the
industry.”

About Enzymotec

Enzymotec is a research-based biotech company that develops, manufactures and markets
innovative lipid-based, bio-functional ingredients and final products. Enzymotec delivers
innovative solutions under three divisions. The Enzymotec Infant Nutrition division
develops lipid compositions that mimic human milk fat to facilitate healthy infant
development.

About Advanced Lipids AB

Advanced Lipids is a joint venture between AAK and Enzymotec for the sales and
marketing of InFat. Advanced Lipids offers InFat as a concentrate form or as any tailored
oil blend enriched with beta-palmitate (high sn2). Advanced Lipids produces InFat at AAK’s
site in Karlshamn, Sweden, based on the enzymatic technology developed by Enzymotec.

        For more information please contact:

        Company contact

        Enzymotec
        Yoav Kahane
        Director of Business Development
        Tel: +972-74-7177177
        Email: info@enzymotec.com
        Web: http://www.enzymotec.com

        Press Contact

        MARKETARGET
        Liat Simha
        Tel: +972-9-9742893
        E-mail: ls@market-targets.com

SOURCE Enzymotec Ltd.